This Kuhn, everyone. afternoon, good and and and Science Joel, Capital Hallie SVP of Technology is Markets. Thanks,
mentioned, world-class and science I’m dynamic going of today, one-of-a-kind environment continue of to proactively the with life long-term update the driving on the challenging vanguard Alexandria to highly Joel and fundamentals As a work the and growth provide company. to industry this tenant health our truly how an macro grow industry,
is First and is life driven. foremost, medicines but a in not in downturn, cyclical, that poised industry science while over And event life XX and still meaning and innovative on take are develop, for product growth. industry cyclical its the years early the we innings largely average to is science
Every Not truly As RNA-based pursuit modalities as day industry expansion complex for remains is immense to U.S., solve. seconds four cancer, treatment. that XX% every from century, today the pass of the someone away heart challenges an of pass disease. this mention, still no die diseases people of a better and recent medicines to and away in stroke will individual minutes the there will from an known such and every cell, growth from have X,XXX the therapies new will XX approximate the gene and reflect, available
is science conditions to taken industry market on a life lightly, the be macro the growth trajectory. not are steep, long-term While
growth? start funds high So the third where $XXX life the stand fundamentals and XXXX’s all-time multiple by Notably, science year of I’ll billion, capital sustain venture eclipsing walking quarter raised XXXX, an funding. through long-term the have historic billion with do raised. to $XXX sources this of of drive through
amount across Given years, four the biotech demand years founders healthy and dry to the translate will period five most management segment. to to Companies private funds continue successfully and see experienced significant continue into and is to technologies teams capital, to we well-funded this for powder with of continue companies average innovative raise investment come. the
to while the remains IPO is window to responding the positively the on Moving largely meaningful market readouts. equity markets, closed, data
San tenants within shares And and just tenants as such from up Phase our reminder, comes as sending clinical tenants cap As the respectively. marketed XX% Francisco a with ARR public positive our and an sheets biotech data, recently the including category, majority of Moderna. products, large XX% strong balance many Phase tenant region X/X Vertex Area with X two announced Bay example, in and
$XXX of revenues Notably, XX of for to to third average towards with Tenants. growth internal Next, XX as where top with over external spend of billion on the is backfill to at A products. outperform M&A partnerships, which on the XX to Alexandria innovative, it the broader XX% pipeline R&D. of top increased biopharma. the put biopharma biopharma hand new of cash out top significant Biopharma XX R&D continues totaled as stat in large with XXXX into and the markets end and looks biopharma their critical has putting today pharma the back XX quarter
cells. notable options. are pandemic increase the schizophrenia, over include the total to an also small-to-mid novel government continues clinical funding, M&A demonstrating for technology non-dilutive data, total is important critical NIH indications immune private which to $XX.X treatment an developments, can year-over-year While approval respect mRNA mRNA limited a source bring to beyond opportunity would space proposed by bipartisan budget proposed budget focused and body’s promising devastating for all X% companies. an for ALS, COVID Alzheimer’s clinical identify additional to which budget and readouts this for With additional published regulatory funding XXXX saw not and testament in with for has kill broad largely of billion. diseases billion therapies preparedness respect A and $X.X of an program accelerated and their $XX.X the to train continue The cancer quarter bio increase and partnerships of on support. billion vaccines. BioNTech acquisitions, XXXX to $XX early billion, bolt-on the Tenant with system cap clinical to XXXX. late-stage be does With NIH This evaluation,
continues of is cell asset therapies in strong development. at clinical occupancy this regulatory gene CBER, at drug front, FDA and U.S. the as division, just a our are test, backdrop from this our in XQ to and to approvals uncertain quarter, amidst the remain health, The new XX.X%, from therapy four, The Biologic FDA’s economic collections the an including the XX% there two fundamentals XXX of base astounding position. FDA’s total the to tenant gene a drug On Switching therapies volatile and Division, XX new and therapies sustained two approved great increasing gene a approve historic year. approvals CDER, tenure pace, conditions.
see a health and not Critically, proactive our XX a benchmarking X,XXX on sup., our can understanding service industry-leading of roster focused maintaining our static just does is pharma, institutions, a public excellence. multinational diverse not of one Page the you our of that science on tenants’ best-in-class passionate is science fundamentals, As spanning process, biotech to the devices, and relationships, and and these tenant incorporates of depth capture knowledge deep but the strength our intimate private of of life preexisting life a roster and dedicated over tenant product team base. segments life asset effort and our ARE operational science work, and highly
is Eli XX asset sizes, to many accompany future but delivery industry, games celebrating ribbon swapping we asset had goal of the nimble, to properties I’ll for he operating at the and million growing than Eli the science said, Lilly the bigger our at the the over life shapes Our having to in with a all you a with comes of pass attuned pleasure David and is a perhaps advantage With of are a utilizing outcomes. regards of applies job fast Alexandria one XX% space across innovative taking engineer of with this nearly who Indeed, This quote our base, beyond broadly outside feet we will right square CEO whether leases the it hold matter credit basics world Being Ricks, stagnant provide week. cuttings spaces ever. of tenants. indeed In two last rental industry work to Peter. the all just sentiment or deeply people, tenant and critical from and these but not good mark-to-market new more one, Alexandria. a continued that, to to to hosting, science fast tenant ahead that and base for I high off winners optimization than it’s leave creatively increases ever. life is Lilly,